Recruiting

Chromium Picolinate

Sponsor:

Nutrition 21, Inc.

Code:

NCT07909109

Conditions

Overweight (BMI > 25)

Appetite

Craving

Eligibility Criteria

Sex: All

Age: 35 - 70

Healthy Volunteers: Accepted

Interventions

Study Product

Study Details

Brief summary:

This open-label, decentralized pilot study evaluates the effects of daily chromium picolinate supplementation (8 mg providing 1,000 mcg chromium) for 8 weeks on appetite, food cravings, and food-related intrusive thoughts ("food noise"). The study aims to enroll up to 110 evaluable healthy adults aged 35-70 years with a body mass index (BMI) between 25 and 31 kg/m². Participants are stratified into two cohorts: those without prior Glucagon-Like Peptide-1 (GLP-1) receptor agonist exposure (Cohort 1, n=80) and those with prior GLP-1 exposure following a 14-to-90-day washout period (Cohort 2, n=30).

Conducted entirely remotely via the Chloe mobile app, the study utilizes validated questionnaires (Food Cravings Questionnaire \[FCQ-T\], RAID-FN food noise inventory, appetite Visual Analogue Scales \[VAS\]), continuous glucose monitoring (CGM), daily meal logs, and weekly adverse event surveys to assess metabolic, behavioral, and subjective outcomes.

Conditions

Overweight (BMI > 25)

Appetite

Craving

Study ID

NCT07909109

Start date

Aug 31, 2026

Status verified date

Oct, 2026

Completion date

Jan, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 35 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Males/Females age 35-70 years old, inclusive
  • Self-reported BMI between 25-31 kg/m²
  • In good general health at the time of screening (Investigator discretion, applied against the objective screening data and the exclusion criteria below - i.e., confirmation that no significant, unlisted comorbidity or acute condition is present that would confound assessment of appetite/craving outcomes or compliance), defined as medically stable for at least the last 6 months.
  • Self-reported weight stable, defined as body weight has not fluctuated significantly over the last 3 months. "Significantly" is defined as a change of more than 3% to 5% of total body weight, or a shift over 5 lbs (Pagidipati 2021) Moderate food cravings, defined as a score 25-54 on the Food Cravings Questionnaire -Reduced (FCQ-15)
  • Able to read and understand English.
  • Able to read, understand, and provide informed consent.
  • Able to use a personal smartphone device and download the Chloe app by People Science.
  • Able to receive shipment of the product and supplies at an address within the United States.
  • Able to complete study assessments over the course of up to 15 weeks.

Exclusion Criteria:

  • Participants actively engaged in weight loss programs or actively dieting.
  • Participants taking any supplements (i.e. fat burners, etc.) specifically for weight loss/management (including appetite control)
  • Participants taking any cinnamon, berberine, or chromium containing supplements.
  • Do not have a personal smartphone, internet access, or unwilling to download Chloe.
  • Current or prior use of a GLP-1 within the last 2 weeks
  • Concomitant Therapies:

Participants receiving any investigational therapies or treatments within 30 days prior to consent.

  • Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:
  • Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder
  • Currently diagnosed with an Eating Disorder
  • Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding
  • Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
  • Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
  • Known hypersensitivity or previous allergic reaction to chromium containing products.
  • Are unlikely for any reason to be able to comply with the trial or considered unsuited for participation in the study by the Principal Investigator.

Study Design

Enrollment

138 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1

Participants who have not had previous GLP-1 exposure.

Cohort 2

Participants with prior GLP-1 exposure. These subjects must undergo a washout period, with self-reported discontinuation of all GLP-1 therapy for a minimum of 14 days, and a maximum of 90 days, prior to study enrollment.

Interventions

Study Product

All 138 Participants will receive similar study product.

Primary outcome measure

  • Impact on hunger and cravings after taking Chromium Picolinate daily [ Time Frame: 10 weeks ]

Central Contacts and Locations

Central contacts

Lisa Capano-Wehrle

8566931265

Locations

People Science

Recruiting

Los Angeles, California, United States, 90045

Contacts

More Information

Sponsor

Nutrition 21, Inc.

Last update posted

Nov 2, 2026

Last verified

Oct, 2026

Keywords

  • craving
  • appetite
  • control cravings

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-03. This information was provided to ClinicalTrials.gov by Nutrition 21, Inc. on 2026-11-02. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.